Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile liquid for intravenous use. It provides passive immunity by replacing deficient IgG antibodies in patients with primary or secondary immunodeficiency disorders.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Iqymune is used in immunoglobulin therapy to replace deficient antibodies in several immune‑related conditions. - Primary Immunodeficiency Diseases: restores IgG levels and reduces the frequency of infections. - Secondary Immunodeficiency (e.g., chemotherapy, HIV): provides IgG replacement to support immune function. - Immune Thrombocytopenic Purpura (ITP): modulates immune response to increase platelet counts.

Administration of Iqymune may be associated with a range of adverse reactions, which are categorised by frequency and severity. Common Side Effects: - Headache: mild to moderate pain often occurring during or shortly after infusion. - Fever and chills: transient rise in body temperature with shaking sensations. - Nausea: mild gastrointestinal discomfort during infusion. - Fatigue: temporary feeling of tiredness post‑treatment. - Infusion‑related reactions: erythema, itching or mild hypotension. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: clot formation that can affect vascular circulation. - Acute renal failure: sudden loss of kidney function, especially with high‑dose regimens.

Before initiating Iqymune therapy, several precautions should be considered to ensure patient safety. - Baseline IgG assessment: measure serum IgG levels to determine need for replacement. - Renal function monitoring: check creatinine and urine output during treatment. - Thrombotic risk evaluation: assess history of clotting disorders before infusion. - IgA deficiency screening: avoid use in patients with severe IgA deficiency and anti‑IgA antibodies. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune can interact with other medicines or vaccines, influencing safety or efficacy. Major Interactions (Avoid): - Live attenuated vaccines: may result in reduced vaccine efficacy; avoid concurrent administration. - High‑dose aspirin or NSAIDs: increase risk of renal impairment when combined with IVIG. - Nephrotoxic agents (e.g., aminoglycosides): may exacerbate renal side effects. Moderate Interactions (Monitor Closely): - Corticosteroids: can mask early signs of infusion reactions; monitor patient response. - Diuretics: may affect fluid balance; observe for volume overload or dehydration. - Inactivated vaccines: immune response may be diminished; assess antibody titres if needed.